Latest Insider Transactions at Hcw Biologics Inc. (HCWB)
This section provides a real-time view of insider transactions for Hcw Biologics Inc. (HCWB). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of HCW Biologics Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of HCW Biologics Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 31
2022
|
Rebecca Byam Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+3.41%
|
$20,000
$2.56 P/Share
|
|
Aug 30
2022
|
Rebecca Byam Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
7,200
+2.57%
|
$14,400
$2.55 P/Share
|
|
Aug 29
2022
|
Rebecca Byam Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+3.63%
|
$20,000
$2.57 P/Share
|
|
Aug 26
2022
|
Rebecca Byam Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+3.76%
|
$20,000
$2.54 P/Share
|
|
Aug 25
2022
|
Rebecca Byam Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
40,300
+14.09%
|
$80,600
$2.59 P/Share
|
|
Aug 24
2022
|
Rebecca Byam Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
50,000
+19.57%
|
$100,000
$2.5 P/Share
|
|
Jun 14
2022
|
Rebecca Byam Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
58,856
+27.46%
|
$117,712
$2.46 P/Share
|
|
Jun 13
2022
|
Rebecca Byam Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
7,596
+7.29%
|
$15,192
$2.08 P/Share
|
|
Jun 10
2022
|
Hing C Wong Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
1,520
+0.01%
|
$3,040
$2.19 P/Share
|
|
Jun 10
2022
|
Gary M Winer |
BUY
Open market or private purchase
|
Direct |
1,500
+10.34%
|
$3,000
$2.13 P/Share
|
|
Jun 09
2022
|
Gary M Winer |
BUY
Open market or private purchase
|
Direct |
1,000
+8.0%
|
$2,000
$2.2 P/Share
|
|
Jun 09
2022
|
Hing C Wong Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
2,000
+0.01%
|
$4,000
$2.25 P/Share
|
|
Jun 08
2022
|
Gary M Winer |
BUY
Open market or private purchase
|
Direct |
1,000
+8.7%
|
$2,000
$2.27 P/Share
|
|
Jun 07
2022
|
Hing C Wong Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
1,000
+0.01%
|
$2,000
$2.31 P/Share
|
|
Jun 07
2022
|
Gary M Winer |
BUY
Open market or private purchase
|
Direct |
1,000
+9.52%
|
$2,000
$2.1 P/Share
|
|
Jun 06
2022
|
Gary M Winer |
BUY
Open market or private purchase
|
Direct |
1,000
+10.53%
|
$2,000
$2.13 P/Share
|
|
Jun 02
2022
|
Rick S. Greene |
BUY
Open market or private purchase
|
Direct |
4,800
+36.33%
|
$9,600
$2.09 P/Share
|
|
May 31
2022
|
Jin An Jiao VP of Development |
BUY
Exercise of conversion of derivative security
|
Direct |
14,570
+13.25%
|
$0
$0.18 P/Share
|
|
Jan 14
2022
|
Peter Rhode Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,715
+1.71%
|
$0
$0.18 P/Share
|
|
Dec 06
2021
|
Jin An Jiao VP of Development |
BUY
Open market or private purchase
|
Direct |
10,000
+24.65%
|
$20,000
$2.42 P/Share
|
|
Dec 01
2021
|
Lee Flowers SVP of Business Development |
BUY
Exercise of conversion of derivative security
|
Direct |
4,285
+4.27%
|
$0
$0.14 P/Share
|
|
Nov 23
2021
|
Rebecca Byam Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
27,000
+23.28%
|
$0
$0.14 P/Share
|
|
Sep 15
2021
|
Medmira Capital Ltd. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
3,587,659
-100.0%
|
-
|
|
Aug 31
2021
|
Hing C Wong Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
3,830
+0.03%
|
$11,490
$3.93 P/Share
|
|
Aug 30
2021
|
Hing C Wong Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
6,000
+0.04%
|
$18,000
$3.93 P/Share
|
|
Aug 27
2021
|
Hing C Wong Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
6,000
+0.04%
|
$18,000
$3.77 P/Share
|
|
Aug 26
2021
|
Hing C Wong Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
6,500
+0.04%
|
$19,500
$3.84 P/Share
|
|
Aug 25
2021
|
Rick S. Greene |
BUY
Open market or private purchase
|
Direct |
3,611
+50.0%
|
$14,444
$4.1 P/Share
|
|
Aug 23
2021
|
Lee Flowers SVP of Business Development |
BUY
Open market or private purchase
|
Direct |
5,605
+5.76%
|
$16,815
$3.95 P/Share
|
|
Aug 20
2021
|
Lee Flowers SVP of Business Development |
BUY
Open market or private purchase
|
Direct |
7,853
+8.36%
|
$31,412
$4.08 P/Share
|
|
Aug 19
2021
|
Rebecca Byam Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+13.89%
|
$40,000
$4.4 P/Share
|
|
Aug 19
2021
|
Lee Flowers SVP of Business Development |
BUY
Open market or private purchase
|
Direct |
10,532
+11.87%
|
$42,128
$4.25 P/Share
|
|
Jul 22
2021
|
Hing C Wong Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
627,500
+3.95%
|
$5,020,000
$8.0 P/Share
|
|
Jul 22
2021
|
Hing C Wong Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
10,342,404
+20.68%
|
-
|
|
Jul 22
2021
|
Rebecca Byam Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
25,000
+32.47%
|
$200,000
$8.0 P/Share
|
|
Jul 22
2021
|
Lee Flowers SVP of Business Development |
BUY
Open market or private purchase
|
Direct |
31,250
+31.59%
|
$250,000
$8.0 P/Share
|
|
Jul 22
2021
|
Peter Rhode Officer |
BUY
Open market or private purchase
|
Direct |
12,500
+21.08%
|
$100,000
$8.0 P/Share
|
|
Jul 22
2021
|
Scott T Garrett |
BUY
Open market or private purchase
|
Indirect |
125,000
+50.0%
|
$1,000,000
$8.0 P/Share
|
|
Jul 22
2021
|
Medmira Capital Ltd. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
3,587,661
+33.46%
|
-
|